<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK544951" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK544951/" /><meta name="ncbi_pagename" content="Adenosine Deaminase 2 Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Adenosine Deaminase 2 Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Adenosine Deaminase 2 Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/08/08" /><meta name="citation_author" content="Ivona Aksentijevich" /><meta name="citation_author" content="Natalia Sampaio Moura" /><meta name="citation_author" content="Karyl Barron" /><meta name="citation_pmid" content="31393689" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK544951/" /><meta name="citation_keywords" content="ADA2 Deficiency" /><meta name="citation_keywords" content="Deficiency of Adenosine Deaminase 2 (DADA2)" /><meta name="citation_keywords" content="ADA2 Deficiency" /><meta name="citation_keywords" content="Deficiency of Adenosine Deaminase 2 (DADA2)" /><meta name="citation_keywords" content="Adenosine deaminase 2" /><meta name="citation_keywords" content="ADA2" /><meta name="citation_keywords" content="Adenosine Deaminase 2 Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Adenosine Deaminase 2 Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Ivona Aksentijevich" /><meta name="DC.Contributor" content="Natalia Sampaio Moura" /><meta name="DC.Contributor" content="Karyl Barron" /><meta name="DC.Date" content="2019/08/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK544951/" /><meta name="description" content="Adenosine deaminase 2 deficiency (DADA2) is a complex systemic autoinflammatory disorder in which vasculopathy/vasculitis, dysregulated immune function, and/or hematologic abnormalities may predominate. Inflammatory features include intermittent fevers, rash (often livedo racemosa/reticularis), and musculoskeletal involvement (myalgia/arthralgia, arthritis, myositis). Vasculitis, which usually begins before age ten years, may manifest as early-onset ischemic (lacunar) and/or hemorrhagic strokes, or as cutaneous or systemic polyarteritis nodosa. Hypertension and hepatosplenomegaly are often found. More severe involvement may lead to progressive central neurologic deficits (dysarthria, ataxia, cranial nerve palsies, cognitive impairment) or to ischemic injury to the kidney, intestine, and/or digits. Dysregulation of immune function can lead to immunodeficiency or autoimmunity of varying severity; lymphadenopathy may be present and some affected individuals have had lymphoproliferative disease. Hematologic disorders may begin early in life or in late adulthood, and can include lymphopenia, neutropenia, pure red cell aplasia, thrombocytopenia, or pancytopenia. Of note, both interfamilial and intrafamilial phenotypic variability (e.g., in age of onset, frequency and severity of manifestations) can be observed; also, individuals with biallelic ADA2 pathogenic variants may remain asymptomatic until adulthood or may never develop clinical manifestations of DADA2." /><meta name="og:title" content="Adenosine Deaminase 2 Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="Adenosine deaminase 2 deficiency (DADA2) is a complex systemic autoinflammatory disorder in which vasculopathy/vasculitis, dysregulated immune function, and/or hematologic abnormalities may predominate. Inflammatory features include intermittent fevers, rash (often livedo racemosa/reticularis), and musculoskeletal involvement (myalgia/arthralgia, arthritis, myositis). Vasculitis, which usually begins before age ten years, may manifest as early-onset ischemic (lacunar) and/or hemorrhagic strokes, or as cutaneous or systemic polyarteritis nodosa. Hypertension and hepatosplenomegaly are often found. More severe involvement may lead to progressive central neurologic deficits (dysarthria, ataxia, cranial nerve palsies, cognitive impairment) or to ischemic injury to the kidney, intestine, and/or digits. Dysregulation of immune function can lead to immunodeficiency or autoimmunity of varying severity; lymphadenopathy may be present and some affected individuals have had lymphoproliferative disease. Hematologic disorders may begin early in life or in late adulthood, and can include lymphopenia, neutropenia, pure red cell aplasia, thrombocytopenia, or pancytopenia. Of note, both interfamilial and intrafamilial phenotypic variability (e.g., in age of onset, frequency and severity of manifestations) can be observed; also, individuals with biallelic ADA2 pathogenic variants may remain asymptomatic until adulthood or may never develop clinical manifestations of DADA2." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK544951/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ada2-def/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK544951/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CAEA1E03FDE21000000000735028B.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK544951_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK544951_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aprt-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ada/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK544951_"><span class="title" itemprop="name">Adenosine Deaminase 2 Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: ADA2 Deficiency, Deficiency of Adenosine Deaminase 2 (DADA2)</div><p class="contrib-group"><span itemprop="author">Ivona Aksentijevich</span>, MD, <span itemprop="author">Natalia Sampaio Moura</span>, BS, and <span itemprop="author">Karyl Barron</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK544951_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK544951_ai__"><div class="contrib half_rhythm"><span itemprop="author">Ivona Aksentijevich</span>, MD<div class="affiliation small">National Human Genome Research Institute<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.smain.bra@iitneska" class="oemail">vog.hin.smain.bra@iitneska</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Natalia Sampaio Moura</span>, BS<div class="affiliation small">National Human Genome Research Institute<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin@aruomoiapmas.ailatan" class="oemail">vog.hin@aruomoiapmas.ailatan</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Karyl Barron</span>, MD<div class="affiliation small">National Institute of Allergy and Infectious Diseases<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin@norrabk" class="oemail">vog.hin@norrabk</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 8, 2019</span>.</p><p><em>Estimated reading time: 29 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ada2-def.Summary" itemprop="description"><h2 id="_ada2-def_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Adenosine deaminase 2 deficiency (DADA2) is a complex systemic autoinflammatory disorder in which vasculopathy/vasculitis, dysregulated immune function, and/or hematologic abnormalities may predominate. Inflammatory features include intermittent fevers, rash (often livedo racemosa/reticularis), and musculoskeletal involvement (myalgia/arthralgia, arthritis, myositis). Vasculitis, which usually begins before age ten years, may manifest as early-onset ischemic (lacunar) and/or hemorrhagic strokes, or as cutaneous or systemic polyarteritis nodosa. Hypertension and hepatosplenomegaly are often found. More severe involvement may lead to progressive central neurologic deficits (dysarthria, ataxia, cranial nerve palsies, cognitive impairment) or to ischemic injury to the kidney, intestine, and/or digits. Dysregulation of immune function can lead to immunodeficiency or autoimmunity of varying severity; lymphadenopathy may be present and some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have had lymphoproliferative disease. Hematologic disorders may begin early in life or in late adulthood, and can include lymphopenia, neutropenia, pure red cell aplasia, thrombocytopenia, or pancytopenia. Of note, both interfamilial and intrafamilial phenotypic variability (e.g., in age of onset, frequency and severity of manifestations) can be observed; also, individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ADA2</i> pathogenic variants may remain asymptomatic until adulthood or may never develop clinical manifestations of DADA2.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of DADA2 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive clinical and laboratory findings and <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>ADA2</i> pathogenic variants identified by molecular testing and/or low (&#x0003c;5% of normal) or undetectable ADA2 catalytic activity in plasma or serum.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Anti-tumor necrosis factor (TNF) agents (etanercept, adalimumab, golimumab, infliximab, certolizumab) are the drugs of choice for both symptomatic and asymptomatic individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ADA2</i> pathogenic variants. They prevent and eliminate manifestations of autoinflammatory disease / vasculitis, reduce the risk of ischemic stroke, reduce inflammatory burden, and relieve immunodeficiency, hepatosplenomegaly, and neutropenia. Anti-TNF agents also improve growth and development in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, and red blood cell and platelet counts; however, anti-TNF agents appear to have little effect in rescuing severe bone marrow abnormalities.</p><p><i>Surveillance:</i> Routine monitoring of clinical and laboratory aspects of DADA2.</p><p><i>Agents/Circumstances to avoid:</i> Antiplatelet medications including aspirin; anticoagulants (except in the presence of atrial fibrillation); and smoking, which may exacerbate peripheral arterial disease.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ADA2</i> pathogenic variants who are currently symptomatic and would benefit from prompt initiation of treatment and those who are currently asymptomatic and would benefit from treatment with anti-TNF agents to reduce the risk of stroke.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>DADA2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (<a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>), and a 25% chance of being unaffected and not a carrier. Once the <i>ADA2</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives, prenatal testing for a pregnancy at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="ada2-def.Diagnosis"><h2 id="_ada2-def_Diagnosis_">Diagnosis</h2><p>Formal diagnostic criteria for adenosine deaminase 2 deficiency (DADA2) have not been established.</p><div id="ada2-def.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Adenosine deaminase 2 deficiency (DADA2) <b>should be suspected</b> in individuals with clinical and laboratory findings of systemic autoinflammatory disease characterized by vasculitis, dysregulation of immune function, and hematologic abnormalities [<a class="bk_pop" href="#ada2-def.REF.hashem.2017b.70">Hashem et al 2017b</a>, <a class="bk_pop" href="#ada2-def.REF.lee.2018.282">Lee 2018</a>, <a class="bk_pop" href="#ada2-def.REF.meyts.2018.569">Meyts &#x00026; Aksentijevich 2018</a>].</p><div id="ada2-def.Systemic_Autoinflammatory_Disea"><h4>Systemic Autoinflammatory Disease</h4><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Intermittent fevers</div></li><li class="half_rhythm"><div>Hepatosplenomegaly (can be evidence of portal hypertension)</div></li><li class="half_rhythm"><div>Systemic hypertension</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div>Elevated C-reactive protein (CRP) and erythrocyte sedimentation rate during flare episodes</div></li><li class="half_rhythm"><div>Elevated transaminases</div></li></ul></div><div id="ada2-def.Vasculitis"><h4>Vasculitis</h4><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Onset. Usually in early childhood (i.e., age &#x0003c;10 years)</div></li><li class="half_rhythm"><div>Skin. Livedo racemosa/reticularis and/or polyarteritis nodosa and/or undifferentiated skin rash</div></li><li class="half_rhythm"><div>Neurologic. Early-onset lacunar and/or hemorrhagic strokes</div></li></ul><p><b>Laboratory findings.</b> Absence of antineutrophilic cytoplasmic antibodies (ANCA)</p><p><b>Imaging findings</b></p><ul><li class="half_rhythm"><div>MRI</div><ul><li class="half_rhythm"><div>Acute or chronic lacunar ischemic infarcts located in the deep-brain nuclei and/or the brain stem and sparing the subcortical white matter</div></li><li class="half_rhythm"><div>Hemorrhagic stroke and intracranial bleeding</div></li></ul></li><li class="half_rhythm"><div>Angiography. Aneurysm or stenosis in medium-sized arteries</div></li></ul></div><div id="ada2-def.Dysregulation_of_Immune_Functio"><h4>Dysregulation of Immune Function</h4><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Immunodeficiency</div></li><li class="half_rhythm"><div>Lymphoproliferative disease including lymphadenopathy</div></li></ul><p><b>Laboratory findings</b></p><ul><li class="half_rhythm"><div>Hypogammaglobulinemia, with low levels of IgM, IgG, and/or IgA. Low serum immunoglobulin levels may correlate with inflammatory disease activity [<a class="bk_pop" href="#ada2-def.REF.schepp.2017.1689">Schepp et al 2017</a>].</div></li><li class="half_rhythm"><div>Impaired production of transitional and switched memory B cells</div></li><li class="half_rhythm"><div>Low vaccine responses noted in some cases</div></li><li class="half_rhythm"><div>Although T cells are largely not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, defective T-cell proliferation, mild-to-profound CD4+ lymphopenia, and low NK counts have been reported [<a class="bk_pop" href="#ada2-def.REF.trotta.2018.1534">Trotta et al 2018</a>].</div></li><li class="half_rhythm"><div>Positive lupus anticoagulant (present in 41% of the Authors' cohort of 41 patients who were tested &#x02013; in which ascertainment could be skewed in favor of individuals with inflammatory findings) [Author, unpublished data]</div></li></ul></div><div id="ada2-def.Hematologic_Abnormalities"><h4>Hematologic Abnormalities</h4><p>Hematologic disorders typically occur early in life; however, in rare instances bone marrow failure may initially appear as late as adulthood (i.e., 5th and 6th decades):</p><ul><li class="half_rhythm"><div>Lymphopenia</div></li><li class="half_rhythm"><div>Neutropenia</div></li><li class="half_rhythm"><div>Pure red cell aplasia</div></li><li class="half_rhythm"><div>Thrombocytopenia</div></li><li class="half_rhythm"><div>Pancytopenia</div></li></ul><p>Bone marrow biopsy may reveal hypo/hypercellularity, grade I myelofibrosis, lymphocyte infiltrate (predominantly CD8+), and mild reticulin fibrosis, further suggesting a defect in cell differentiation. In one individual the bone marrow showed a reduced number of CD138+ plasma cells [<a class="bk_pop" href="#ada2-def.REF.zhou.2014.911">Zhou et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.van_eyck.2015.283">Van Eyck et al 2015</a>, <a class="bk_pop" href="#ada2-def.REF.benami.2016.316">Ben-Ami et al 2016</a>, <a class="bk_pop" href="#ada2-def.REF.hashem.2017a.e293">Hashem et al 2017a</a>, <a class="bk_pop" href="#ada2-def.REF.michniacki.2018.166">Michniacki et al 2018</a>, <a class="bk_pop" href="#ada2-def.REF.trotta.2018.1534">Trotta et al 2018</a>].</p></div><div id="ada2-def.Other"><h4>Other</h4><p><b>Other clinical findings</b> include musculoskeletal features, aphthous ulcers, inflammatory bowel disease-like illness, and hearing loss.</p><p><b>Other laboratory findings.</b> In contrast to individuals with an inherited <a href="/books/n/gene/ada/">deficiency of ADA</a>, persons with DADA2 do not have profound lymphopenia and their erythrocytes have normal levels of ADA activity and undetectable (rather than elevated) levels of deoxyadenosine triphosphate or total deoxyadenosine nucleotides.</p></div></div><div id="ada2-def.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of DADA2 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with <a href="#ada2-def.Suggestive_Findings">suggestive findings</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <i>ADA2</i> pathogenic variants on molecular testing (<a class="figpopup" href="/books/NBK544951/table/ada2-def.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="figada2defTmoleculargenetictestinguse" rid-ob="figobada2defTmoleculargenetictestinguse">Table 1</a>) and/or low (&#x0003c;5% of normal) or undetectable plasma ADA2 catalytic activity. Note: While both tests are diagnostic, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is more widely available.</p><p><b>Molecular genetic testing</b> approaches can include a combination of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of DADA2 is broad, individuals with some of the distinctive findings described in <a href="#ada2-def.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#ada2-def.Option_1">Option 1</a>), whereas those in whom the diagnosis of DADA2 has not been considered are more likely to be diagnosed using genomic testing (see <a href="#ada2-def.Option_2">Option 2</a>).</p><div id="ada2-def.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of DADA2 <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>. Among 66 individuals who were clinically suspected of having DADA2 and underwent genetic analysis at a French referral center for autoinflammatory disorders, 13 individuals from 11 families (20%) were found to have <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ADA2</i> pathogenic variants [<a class="bk_pop" href="#ada2-def.REF.rama.2018.960">Rama et al 2018</a>]. Among those with DADA2, more than 80% had a combination of a biomarker of inflammation (fever, elevated CRP), evidence of vasculitis (cutaneous, neurologic), and more than one clinical flare. Of note, these criteria may not apply to individuals who present with hematologic manifestations only [<a class="bk_pop" href="#ada2-def.REF.benami.2016.316">Ben-Ami et al 2016</a>, <a class="bk_pop" href="#ada2-def.REF.s_nmez.2018.1563">S&#x000f6;nmez et al 2018</a>].</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ADA2</i> detects <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a>, <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a>, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. In individuals with a highly suspicious clinical presentation and or/low plasma/serum ADA2 activity in whom only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, performing gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> may detect intragenic deletions or duplications (i.e., copy number variants).</p><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ADA2</i> and other genes associated with immune dysregulation, primary immunodeficiency, or autoinflammatory syndromes (see <a href="#ada2-def.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify a genetic cause at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) Some laboratories offer custom-designed panels and/or phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For diagnosis of DADA2 a multigene panel that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="figada2defTmoleculargenetictestinguse" rid-ob="figobada2defTmoleculargenetictestinguse">Table 1</a>).</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p></div><div id="ada2-def.Option_2"><h4>Option 2</h4><p>When the diagnosis of DADA2 has not been considered because an individual has atypical phenotypic features, <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible. If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> identifies only one <i>ADA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, perform <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="ada2-def.T.molecular_genetic_testing_use" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Adenosine Deaminase 2 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK544951/table/ada2-def.T.molecular_genetic_testing_use/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ada2-def.T.molecular_genetic_testing_use_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ADA2</i></td><td headers="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~97%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_ada2-def.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~3%%&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ada2-def.TF.1.1"><p class="no_margin">See <a href="/books/NBK544951/#ada2-def.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ada2-def.TF.1.2"><p class="no_margin">See <a href="#ada2-def.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ada2-def.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ada2-def.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#ada2-def.REF.hashem.2017b.70">Hashem et al [2017b]</a>, <a class="bk_pop" href="#ada2-def.REF.meyts.2018.569">Meyts &#x00026; Aksentijevich [2018]</a></p></div></dd><dt>5. </dt><dd><div id="ada2-def.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="ada2-def.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#ada2-def.REF.zhou.2014.911">Zhou et al [2014]</a>, <a class="bk_pop" href="#ada2-def.REF.fellmann.2016.1189">Fellmann et al [2016]</a>, <a class="bk_pop" href="#ada2-def.REF.uettwiller.2016.e000236">Uettwiller et al [2016]</a>, <a class="bk_pop" href="#ada2-def.REF.lee.2018.1363">Lee et al [2018]</a>, <a class="bk_pop" href="#ada2-def.REF.grossi.2019.732">Grossi et al [2019]</a></p></div></dd></dl></div></div></div><p><b>ADA2 enzyme activity.</b> In humans, the enzyme ADA2 is present in plasma and myeloid cells, but not in erythrocytes. DADA2 is associated with low (&#x0003c;5% of normal) or absent ADA2 enzymatic activity in serum or plasma (fresh or stored frozen samples). DADA2 can also be diagnosed by measuring ADA2 activity in extracts of dried plasma spots on filter paper [<a class="bk_pop" href="#ada2-def.REF.benami.2016.316">Ben-Ami et al 2016</a>]. The two biochemical assays used are ELISA (enzyme-linked immunosorbent assay) and HPLC (high-performance liquid chromatography).</p><p>Note: (1) An ELISA-based assay for ADA2 activity is commonly used in research laboratories but may not be available in clinical laboratories; (2) although deficiency of immuno-precipitable ADA2 enzyme has been demonstrated in persons with DADA2 [<a class="bk_pop" href="#ada2-def.REF.zhou.2014.911">Zhou et al 2014</a>], no anti-ADA2 antibody-based method has been validated for use in clinical laboratories.</p></div></div></div><div id="ada2-def.Clinical_Characteristics"><h2 id="_ada2-def_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ada2-def.Clinical_Description"><h3>Clinical Description</h3><p>Deficiency of adenosine deaminase 2 (DADA2) is a systemic autoinflammatory disorder in which the three major manifestations are vasculitis, dysregulation of immune function, and hematologic disease [<a class="bk_pop" href="#ada2-def.REF.hashem.2017b.70">Hashem et al 2017b</a>, <a class="bk_pop" href="#ada2-def.REF.lee.2018.282">Lee 2018</a>, <a class="bk_pop" href="#ada2-def.REF.meyts.2018.569">Meyts &#x00026; Aksentijevich 2018</a>]. Other clinical features include neurologic, gastrointestinal, and musculoskeletal involvement. Severe manifestations (e.g., strokes or ischemic injuries to tissues and/or organs) can cause disability and/or be life threatening. Prior to the discovery of the molecular pathogenesis of DADA2 and adequate therapies, death before age 30 years was reported in 8% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ada2-def.REF.hashem.2017b.70">Hashem et al 2017b</a>, <a class="bk_pop" href="#ada2-def.REF.meyts.2018.569">Meyts &#x00026; Aksentijevich 2018</a>].</p><p>Phenotypic variability that cannot be fully explained by the effect of pathogenic variants on protein function can be observed in the same family; for example, one sib may have have early-childhood onset of manifestations whereas another may have later-childhood onset. Affected individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the same <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> have variability in age of onset and in frequency and severity of manifestations [<a class="bk_pop" href="#ada2-def.REF.van_montfrans.2016.902">Van Montfrans et al 2016</a>]. In a large family of Iraqi descent, four adults homozygous for the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> were symptom free despite low ADA2 activity [<a class="bk_pop" href="#ada2-def.REF.nanthapisal.2016.2314">Nanthapisal et al 2016</a>].</p><div id="ada2-def.Vasculitis_1"><h4>Vasculitis</h4><p>The most frequent manifestations of DADA2 are related to arterial vasculopathy which often manifests as cutaneous lesions. Cutaneous manifestations, reported in more than 75% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, include livedo racemosa/reticularis, polyarteritis nodosa (PAN), subcutaneous nodules, cutaneous ulcers, or lupus-like rash [<a class="bk_pop" href="#ada2-def.REF.gonzalez_santiago.2015.1230">Gonzalez Santiago et al 2015</a>, <a class="bk_pop" href="#ada2-def.REF.caorsi.2016.51">Caorsi et al 2016</a>, <a class="bk_pop" href="#ada2-def.REF.skrablbaumgartner.2017.67">Skrabl-Baumgartner et al 2017</a>].</p><p>Histopathologic findings of DADA2-associated PAN and PAN of unknown cause are the same: non-granulomatous, necrotizing vasculitis of small and medium-sized vessels. Sometimes less specific findings are interpreted as leukocytoclastic vasculitis. In younger individuals with livedoid rash, skin biopsy shows interstitial neutrophil and macrophage infiltration without overt vasculitis.</p><p>In one study, nine (15%) of 60 children with PAN, cutaneous PAN, unclassifiable vasculitis (UCV), young-onset chronic vasculitis, or history of stroke were found to have biallleic <i>ADA2</i> pathogenic variants. Previous clinical diagnoses included PAN (5 children), UCV (3), and ANCA-associated vasculitis (1) [<a class="bk_pop" href="#ada2-def.REF.gibson.2019">Gibson et al 2019</a>].</p><p>Ischemic strokes are often observed in (but not limited to) the brain stem, thalamus, basal ganglia, and internal capsule [<a class="bk_pop" href="#ada2-def.REF.bulut.2019.193">Bulut et al 2019</a>]. These small infarcts, described as lacunar strokes, may not always be observable on MRI.</p><p>Over time accumulation of the effects of these small initially undetectable strokes can lead to severe neurologic impairments such as persistent dysarthria, ataxia, palsy of one or more cranial nerves, and cognitive impairment [<a class="bk_pop" href="#ada2-def.REF.springer.2018.1361">Springer et al 2018</a>].</p><p>Other neurologic manifestations can include the following:</p><ul><li class="half_rhythm"><div>Small, deep intracerebral hemorrhage. Specifically, hemorrhagic strokes were observed on MRI and/or CT in the ventricular system and right frontal insula in different individuals. Most often they occur in the setting of concomitant use of antiplatelet or anticoagulant therapy; however, on rare occasion they may occur spontaneously [<a class="bk_pop" href="#ada2-def.REF.belot.2014.44">Belot et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.garg.2014.827">Garg et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.navon_elkan.2014.921">Navon Elkan et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.zhou.2014.911">Zhou et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.nanthapisal.2016.2314">Nanthapisal et al 2016</a>, <a class="bk_pop" href="#ada2-def.REF.lee.2018.1363">Lee et al 2018</a>].</div></li><li class="half_rhythm"><div>Cerebral vessel aneurysm (1 patient) [<a class="bk_pop" href="#ada2-def.REF.navon_elkan.2014.921">Navon Elkan et al 2014</a>]</div></li><li class="half_rhythm"><div>Seizures resulting from strokes. Manifestations are related to the location of the stroke.</div></li><li class="half_rhythm"><div>Central and peripheral neuropathy. The diverse manifestations reported include cranial nerve palsies, sensorineural hearing loss, and ophthalmologic complications [<a class="bk_pop" href="#ada2-def.REF.lee.2018.282">Lee 2018</a>].</div></li></ul><p>Other effects of distal artery occlusion include peripheral vascular insufficiency, digital necrosis, and Raynaud phenomena [<a class="bk_pop" href="#ada2-def.REF.navon_elkan.2014.921">Navon Elkan et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.zhou.2014.911">Zhou et al 2014</a>].</p><p><b>GI manifestations</b> generally include abdominal pain and chronic gastritis. On rare occasions, intestinal necrosis, bowel perforation, and arterial stenosis are observed [<a class="bk_pop" href="#ada2-def.REF.belot.2014.44">Belot et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.batu.2015.1532">Batu et al 2015</a>].</p><p><b>Hepatic disease</b> involves hepatomegaly and splenomegaly that can lead to portal hypertension and associated esophageal varices. Histopathologic findings include evidence of nodular regenerative hyperplasia and/or hepatic sclerosis that can potentially lead to end-stage liver disease [<a class="bk_pop" href="#ada2-def.REF.springer.2018.1361">Springer et al 2018</a>].</p><p>Other organs with dense vascularization such as the kidney can be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. Multiple aneurysmal dilatations and variation in the caliber of medium-small intrarenal arteries have been reported as well as renal artery stenosis and infarcts [<a class="bk_pop" href="#ada2-def.REF.navon_elkan.2014.921">Navon Elkan et al 2014</a>, <a class="bk_pop" href="#ada2-def.REF.nanthapisal.2016.2314">Nanthapisal et al 2016</a>, <a class="bk_pop" href="#ada2-def.REF.sahin.2018.129">Sahin et al 2018</a>].</p></div><div id="ada2-def.Dysregulation_of_Immune_Functio_1"><h4>Dysregulation of Immune Function</h4><p>General dysregulation of immune function can include immunodeficiency, lymphoproliferative disease, and autoimmune manifestations of varying severity.</p><p><b>Immunodeficiency.</b> While the autoinflammatory <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> was predominant in the initial description of DADA2, mild immunodeficiency was identified in five of nine patients in the cohort [<a class="bk_pop" href="#ada2-def.REF.zhou.2014.911">Zhou et al 2014</a>]. Intially it was not clear if immunodeficiency could be related to the use of immunosuppressive therapies; however, subsequently in the German cohort of 181 individuals with antibody deficiency and/or features of common variable immunodeficiency, eleven individuals were found to have DADA2 [<a class="bk_pop" href="#ada2-def.REF.schepp.2016.179">Schepp et al 2016</a>, <a class="bk_pop" href="#ada2-def.REF.schepp.2017.1689">Schepp et al 2017</a>]; of these, four presented with immunodeficiency without vascular manifestations. To date the spectrum of immunodeficiency includes variable degrees of B-cell depletion and hypogammaglobulinemia. T-cell numbers are largely unaffected except in patients with bone marrow failure.</p><p>About 20% of individuals with DADA2 experience bacterial and/or viral infections resulting from immunodeficiency. Bacterial infections typicaly involve the upper- and lower-respiratory tract, gastrointestinal tract, and urinary tract. Viral infections have included recurrent herpes simplex infections, skin warts (caused by the human papilloma virus) [<a class="bk_pop" href="#ada2-def.REF.arts.2018.836">Arts et al 2018</a>], and in one child, shingles (caused by the herpes zoster virus) [<a class="bk_pop" href="#ada2-def.REF.ghurye.2019.e60">Ghurye et al 2019</a>].</p><p>Although fungal and mycobacterial infections are unusual, they were observed in one individual with severe monocytopenia [<a class="bk_pop" href="#ada2-def.REF.hsu.2016">Hsu et al 2016</a>] and in two sibs with a <a class="def" href="/books/n/gene/glossary/def-item/contiguous-gene-deletion/">contiguous gene deletion</a> involving <i>ADA2</i> and <i>IL-17RA</i> in whom recurrent fungal infections were attributed to IL-17R deficiency [<a class="bk_pop" href="#ada2-def.REF.fellmann.2016.1189">Fellmann et al 2016</a>].</p><p><b>Lymphoproliferative disease.</b> Generalized lymphadenopathy is seen in more than 10% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; splenomegaly is fairly common. The lymphoproliferative <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of DADA2 can include the following:</p><ul><li class="half_rhythm"><div>Features mimicking the following disorders:</div><ul><li class="half_rhythm"><div>GATA2 deficiency [<a class="bk_pop" href="#ada2-def.REF.hsu.2016">Hsu et al 2016</a>]</div></li><li class="half_rhythm"><div><a href="/books/n/gene/alps/">Autoimmune lymphoproliferative syndrome</a> (ALPS) [<a class="bk_pop" href="#ada2-def.REF.alsultan.2018.65">Alsultan et al 2018</a>, <a class="bk_pop" href="#ada2-def.REF.barzaghi.2019.2767">Barzaghi et al 2019</a>]</div></li><li class="half_rhythm"><div>Multicentric Castleman disease [<a class="bk_pop" href="#ada2-def.REF.van_nieuwenhove.2018.142">Van Nieuwenhove et al 2018</a>]</div></li></ul></li><li class="half_rhythm"><div>CD3+ CD8+ T-cell large granular lymphocytic (T-LGL) infiltration of the bone marrow (in 2 individuals) [<a class="bk_pop" href="#ada2-def.REF.trotta.2018.1534">Trotta et al 2018</a>].</div></li><li class="half_rhythm"><div>Adolescent-onset Hodgkin's lymphoma (HL) was initialy reported in one individual (however, definitive supporting evidence for HL was not available) [<a class="bk_pop" href="#ada2-def.REF.springer.2018.1361">Springer et al 2018</a>]. More recently, childhood-onset HL was histopathologically confirmed in two sibs with DADA2 [<a class="bk_pop" href="#ada2-def.REF.alabbas.2019.26">Alabbas et al 2019</a>].</div></li></ul><p><b>Autoimmune disease</b> resembling systemic lupus erythematosus and autoimmune cytopenia was reported in two unrelated families [<a class="bk_pop" href="#ada2-def.REF.schepp.2016.179">Schepp et al 2016</a>, <a class="bk_pop" href="#ada2-def.REF.skrablbaumgartner.2017.67">Skrabl-Baumgartner et al 2017</a>].</p></div><div id="ada2-def.Hematologic_Disease"><h4>Hematologic Disease</h4><p>Hematopoietic complications include variably decreased numbers of leukocytes, platelets, and erythrocytes (including pure red cell aplasia [PRCA] similar to <a href="/books/n/gene/diamond-b/">Blackfan-Diamond anemia</a>), as well as pancytopenia due to complete bone marrow failure. A meta-analysis of published data on 161 individuals with DADA2 revealed anemia in 13%, neutropenia in 7%, and thrombocytopenia in 6%, whereas leukopenia, PRCA, NK cell deficiency, and pancytopenia were observed in fewer than 5% [<a class="bk_pop" href="#ada2-def.REF.meyts.2018.569">Meyts &#x00026; Aksentijevich 2018</a>].</p><p>The initial clinical presentation in five children from four unrelated <a class="def" href="/books/n/gene/glossary/def-item/consanguineous/">consanguineous</a> families was PRCA and hemolytic anemia without manifestations of inflammation or vasculitis [<a class="bk_pop" href="#ada2-def.REF.benami.2016.316">Ben-Ami et al 2016</a>].</p><p>Neutropenia was severe (i.e., low or absent absolute neutrophil counts) in two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ada2-def.REF.hashem.2017a.e293">Hashem et al 2017a</a>, <a class="bk_pop" href="#ada2-def.REF.cipe.2018.273">Cipe et al 2018</a>] and moderate but persistent in other affected individuals [<a class="bk_pop" href="#ada2-def.REF.ghurye.2019.e60">Ghurye et al 2019</a>].</p></div><div id="ada2-def.Musculoskeletal_Manifestations"><h4>Musculoskeletal Manifestations</h4><p>About 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have the following musculoskeletal manifestations: myalgia/arthralgia (22%), arthritis (14%), and myositis (1%) [<a class="bk_pop" href="#ada2-def.REF.meyts.2018.569">Meyts &#x00026; Aksentijevich 2018</a>, <a class="bk_pop" href="#ada2-def.REF.sahin.2019">Sahin et al 2019</a>]. Musculoskeletal manifestations are often accompanied by other features of systemic inflammation, such as fevers and/or elevated acute-phase reactants.</p></div></div><div id="ada2-def.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>To date no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> associating ADA2 pathogenic variants with the clinical presentation of DADA2 have been identified.</p><p>Studies of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in the two major founder populations in the Middle East and northern Europe could possibly offer insight into some <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a>. See <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.notable_ada2_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figada2defTnotableada2pathogenicvaria" rid-ob="figobada2defTnotableada2pathogenicvaria">Table 3</a> for more details.</p><ul><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.notable_ada2_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figada2defTnotableada2pathogenicvaria" rid-ob="figobada2defTnotableada2pathogenicvaria">p.Gly47Arg</a> <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>, identified in 19 individuals of Georgian-Jewish ancestry and 15 individuals of Turkish ancestry, was associated with the clinical diagnosis of childhood-onset cutaneous polyarteritis nodosa (despite some clinical variability).</div></li><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.notable_ada2_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figada2defTnotableada2pathogenicvaria" rid-ob="figobada2defTnotableada2pathogenicvaria">p.Arg169Gln</a> <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> identified in nine Dutch individuals was associated with significant variability in disease onset as well as frequency and severity of manifestations among <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs [<a class="bk_pop" href="#ada2-def.REF.van_montfrans.2016.902">Van Montfrans et al 2016</a>]. Compared to the p.Gly47Arg variant, the cutaneous and visceral manifestations associated with the p.Arg169Gln variant in general were less severe, whereas neurologic and hematologic manifestations were more common.</div></li><li class="half_rhythm"><div>In a large family of Iraqi descent two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and four unaffected members <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.notable_ada2_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figada2defTnotableada2pathogenicvaria" rid-ob="figobada2defTnotableada2pathogenicvaria">p.Pro251Leu</a> had low ADA2 activity irrespective of disease status, indicating <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> of the clinical features of DADA2 [<a class="bk_pop" href="#ada2-def.REF.nanthapisal.2016.2314">Nanthapisal et al 2016</a>].</div></li></ul></div><div id="ada2-def.Prevalence"><h3>Prevalence</h3><p>DADA2 is considered a rare disease; however, since its initial description in 2014, more than 170 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been reported in the literature. Based on <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> frequencies of in silico-predicted <i>ADA2</i> damaging variants, the estimated prevalence of DADA2 could be as high as 4:100,000.</p><p>DADA2 prevalence is higher in populations with a high degree of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a> or in populations with founder variants. See <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.notable_ada2_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="figada2defTnotableada2pathogenicvaria" rid-ob="figobada2defTnotableada2pathogenicvaria">Table 3</a>.</p><ul><li class="half_rhythm"><div>Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from the Middle East are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the p.Gly47Arg <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>. The highest <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency for this variant is reported in the Georgian-Jewish population (1:10); the estimated carrier frequency of this variant in the Turkish population is about 1:500.</div></li><li class="half_rhythm"><div>The p.Arg169Gln <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> has an estimated <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of 1:500 in northern European populations (Finnish, Dutch). The <a class="def" href="/books/n/gene/glossary/def-item/allele-frequency/">allele frequency</a> is significantly lower in African, Latino, and Asian populations.</div></li></ul></div></div><div id="ada2-def.Genetically_Related_Allelic_Dis"><h2 id="_ada2-def_Genetically_Related_Allelic_Dis_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>ADA2</i>.</p></div><div id="ada2-def.Differential_Diagnosis"><h2 id="_ada2-def_Differential_Diagnosis_">Differential Diagnosis</h2><p>Inherited disorders to consider in the differential diagnosis of DADA2 are included in <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.inherited_disorders_with_norm/?report=objectonly" target="object" rid-figpopup="figada2defTinheriteddisorderswithnorm" rid-ob="figobada2defTinheriteddisorderswithnorm">Table 2</a>; disorders without a known genetic component to consider in the differential diagnosis are discussed following <a class="figpopup" href="/books/NBK544951/table/ada2-def.T.inherited_disorders_with_norm/?report=objectonly" target="object" rid-figpopup="figada2defTinheriteddisorderswithnorm" rid-ob="figobada2defTinheriteddisorderswithnorm">Table 2</a>.</p><div id="ada2-def.T.inherited_disorders_with_norm" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Inherited Disorders with Normal ADA2 Enzyme Activity to Consider in the Differential Diagnosis of Adenosine Deaminase 2 Deficiency (DADA2)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK544951/table/ada2-def.T.inherited_disorders_with_norm/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ada2-def.T.inherited_disorders_with_norm_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential Diagnosis Disorder</th><th id="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4" id="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/DADA2</th><th headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4" id="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from DADA2</th></tr></thead><tbody><tr><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/diamond-b/">Diamond-Blackfan anemia</a> (DBA)</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12 ribosomal protein genes,<br /><i>GATA1</i>,<br /><i>TSR2</i></td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pure red cell aplasia</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May have microcephaly, cleft palate &#x00026; distinctive facies (hypertelorism, broad flat nasal bridge)</td></tr><tr><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ADA-SCID&#x000a0;<sup>1</sup></td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ADA</i></td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immune deficiency</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Immune deficiency is much more severe.</div></li><li class="half_rhythm"><div>Depletion of T, B, &#x00026; NK cells</div></li><li class="half_rhythm"><div>Low levels of ADA</div></li><li class="half_rhythm"><div>Lack cerebrovascular disease &#x00026; cutaneous manifestations</div></li></ul></td></tr><tr><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">GATA2 deficiency (OMIM <a href="https://omim.org/entry/614172" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">614172</a>)</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GATA2</i></td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immune deficiency, cytopenia, recurrent infections&#x000a0;<sup>2</sup></td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Infections are often invasive.</div></li><li class="half_rhythm"><div>Vasculitic complications are rare.</div></li></ul></td></tr><tr><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/alps/">Autoimmune lymphoproliferative syndrome</a> (ALPS)</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CASP10</i>,<br /><i>FAS</i>,<br /><i>FASLG</i>&#x000a0;<sup>3</sup></td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD<br />AR</td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Lymphadenopathy, splenomegaly, immune-mediated cytopenia&#x000a0;<sup>4</sup></td><td headers="hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_1_4 hd_h_ada2-def.T.inherited_disorders_with_norm_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ALPS, caused by primary defect in programmed cell death, has more autoimmune features.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="ada2-def.TF.2.1"><p class="no_margin">ADA-SCID = severe combined immune deficiency caused by <a href="/books/n/gene/ada/">adenosine deaminase defects</a></p></div></dd><dt>2. </dt><dd><div id="ada2-def.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#ada2-def.REF.hsu.2016">Hsu et al [2016]</a></p></div></dd><dt>3. </dt><dd><div id="ada2-def.TF.2.3"><p class="no_margin">Approximately 20%-25% of individuals with ALPS lack a genetic diagnosis (see <a href="/books/n/gene/alps/">ALPS</a>).</p></div></dd><dt>4. </dt><dd><div id="ada2-def.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#ada2-def.REF.alsultan.2018.65">Alsultan et al [2018]</a></p></div></dd></dl></div></div></div><p>Disorders with normal ADA2 enzyme activity and without a known genetic component include the following:</p><ul><li class="half_rhythm"><div><b>Polyarteritis nodosa</b> characterized by vasculitis/vasculopathy, livedo, skin nodules and aneurysms of medium-sized arteries. Features of DADA2 not observed are strokes, hematologic disorders, and immune deficiency.</div></li><li class="half_rhythm"><div><b>Sneddon syndrome</b> characterized by livedo racemosa, Raynaud phenomenon, and noninflammatory thrombotic cerebral vasculopathy. It can be associated with systemic lupus erythematosus and antiphospholipid syndrome (antiphospholipid antibodies are detected in ~50% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals). It is more common in women and onset is usually in or after the second decade of life. While most occurrences are <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family), some individuals have a positive family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance [<a class="bk_pop" href="#ada2-def.REF.goel.1999.318">Goel et al 1999</a>, <a class="bk_pop" href="#ada2-def.REF.hademenos.2001.997">Hademenos et al 2001</a>, <a class="bk_pop" href="#ada2-def.REF.szmyrkakaczmarek.2005">Szmyrka-Kaczmarek et al 2005</a>].</div></li><li class="half_rhythm"><div><b>Autoimmune neutropenia</b> characterized by absolute to low neutrophil counts. It is often present in persons with systemic lupus erythematosus or other autoimmune diseases. Of note, in autoimmune diseases, neutropenia is mediated by autoantibodies and other clinical features of DADA2 are absent; in contrast, in DADA2 the mechanism of neutropenia is unclear.</div></li><li class="half_rhythm"><div><b>CVID.</b> About 5%-6% of individuals diagnosed with common variable immunodeficiency (CVID) and antibody deficiency were found to have DADA2 on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> [<a class="bk_pop" href="#ada2-def.REF.schepp.2017.1689">Schepp et al 2017</a>].</div></li><li class="half_rhythm"><div><b>Myalgia/myositis, fibromyalgia, and arthralgia/arthritis</b> observed in about 20% of individuals with DADA2 resemble the findings of juvenile <a class="def" href="/books/n/gene/glossary/def-item/idiopathic/">idiopathic</a> arthritis.</div></li></ul></div><div id="ada2-def.Management"><h2 id="_ada2-def_Management_">Management</h2><div id="ada2-def.Evaluations_Following_Initial_D"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with adenosine deaminase 2 deficiency (DADA2), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><ul><li class="half_rhythm"><div><b>Complete physical examination</b> with emphasis on:</div><ul><li class="half_rhythm"><div>Blood pressure and other vital signs, as systemic hypertension and/or fever are common.</div></li><li class="half_rhythm"><div>Skin examination for evidence of livedo reticularis/racemosa, nodules, and Raynaud phenomenon. Severe involvement can include digital infarcts/gangrene or skin ulcerations.</div></li><li class="half_rhythm"><div>Assessment for lymphadenopathy and hepatosplenomegaly.</div></li><li class="half_rhythm"><div>Neurologic examination for evidence of prior or recent strokes.</div></li></ul></li><li class="half_rhythm"><div><b>Ophthalmologic examination</b> for vision loss, diplopia, retinal infarcts, optic nerve damage, uveitis, ptosis, strabismus, and nystagmus</div></li><li class="half_rhythm"><div><b>Electrocardiogram</b> (ECG) for manifestations of portal hypertension, including prolonged QT interval</div></li><li class="half_rhythm"><div><b>Laboratory assessment</b></div><ul><li class="half_rhythm"><div>Complete blood count (CBC) with differential to detect anemia, lymphopenia, neutropenia, and/or thrombocytopenia</div></li><li class="half_rhythm"><div>Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as elevated levels may correlate with disease activity</div></li><li class="half_rhythm"><div>Kidney and liver function tests</div></li><li class="half_rhythm"><div>Quantitative serum immunoglobulins</div></li><li class="half_rhythm"><div>PT/PTT to assess the risk of stroke in a patient who has not had a stroke OR to assess the risk of subsequent strokes in those who have had a stroke</div></li><li class="half_rhythm"><div>Autoantibodies including antinuclear antibodies and lupus anticoagulant. Low titers are reported in 10% of patients, whereas high titers suggest other autoimmune diseases, such as systemic lupus erythematous.</div></li><li class="half_rhythm"><div>Antineutrophilic cytoplasmic antibodies (ANCA) are usually absent; their presence suggests ANCA-related vasculitis.</div></li><li class="half_rhythm"><div>Lymphocyte phenotyping. Failure to develop memory B-cells, a common finding, is evidence of a B-cell maturation defect that warrants further evaluation of the immune system (quantitative serum immunoglobulins, antibody response to vaccines, and history of severe and/or multiple infections). Failure to develop memory T-cells may be seen but is uncommon.</div></li><li class="half_rhythm"><div>Antibody response to vaccines. Inadequate response suggests immune deficiency.</div></li></ul></li><li class="half_rhythm"><div><b>Imaging assessment</b></div><ul><li class="half_rhythm"><div>Brain MRI in all patients, even those without overt neurologic manifestations, as a baseline given that small strokes can be clinically silent</div></li><li class="half_rhythm"><div>Magnetic resonance angiography (MRA):</div><ul><li class="half_rhythm"><div>When brain MRI is abnormal, brain MRA (which is expected to be normal in persons with DADA2) can help differentiate the cause of stroke.</div></li><li class="half_rhythm"><div>Abnormal peripheral MRA may suggest additional treatment options to improve vascular flow for cutaneous lesions (e.g., vascular insufficiency, infarcts, gangrene) or neurologic dysfunction, such as peripheral neuropathy).</div></li></ul></li><li class="half_rhythm"><div>Renal ultrasound examination to assess kidney size (which can be smaller due to poor vascularization and/or infarcts), function, and blood flow. Reported abnormalities that merit documentation before intiation of treatment include renal artery aneurysm and stenosis, renal infarcts (which may be silent), renal inflammation with dense lymphocytic infiltration, and glomerular scarring.</div></li><li class="half_rhythm"><div>Abdominal ultrasound examination to provide baseline assessment of liver and spleen size and hepatic blood flow. Splenomegaly occurs in up to 30% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, hepatomegaly in 20%.</div></li><li class="half_rhythm"><div>FibroScan<sup>&#x000ae;</sup> ultrasound examination (if available) to assess baseline hepatic elasticity (because early portal hypertension can be clinically silent)</div></li></ul></li><li class="half_rhythm"><div><b>Other</b></div><ul><li class="half_rhythm"><div>When clinically indicated:</div><ul><li class="half_rhythm"><div>Skin biopsy in order to document vasculitis, or to investigate an atypical rash</div></li><li class="half_rhythm"><div>Liver biopsy to assess cause of hepatomegaly and presence of hepatic steatosis and/or nodular regenerative sclerosis</div></li></ul></li><li class="half_rhythm"><div>Evaluation for manifestations of portal hypertension. If present, perform endoscopy to assess its extent.</div></li></ul></li><li class="half_rhythm"><div><b>Consultation with a clinical geneticist and/or genetic counselor</b></div></li></ul></div><div id="ada2-def.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="ada2-def.Current_Treatment_for_Persons_w"><h4>Current Treatment for Persons with Symptomatic DADA2</h4><p><b>Anti-tumor necrosis factor (TNF) agents</b> (also known as "biologics") including etanercept, adalimumab, golimumab, infliximab, and certolizumab are the drugs of choice to prevent and eliminate manifestations of autoinflammatory disease / vasculitis. Use of such drugs reduces risk of ischemic stroke and inflammatory burden (as shown by lower CRP/ESR levels and less skin rash) and relieves immunodeficiency, hepatosplenomegaly, and neutropenia. In a cohort of 15 patients with DADA2 who had a total of 37 strokes before the initiation of anti-TNF therapy, no strokes were observed post treatment [<a class="bk_pop" href="#ada2-def.REF.ombrello.2019.1582">Ombrello et al 2019</a>]. Use of such drugs also increases growth and development in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children, and improves red blood cell and platelet counts due to relief of the inflammatory burden. Of note, anti-TNF agents appear to have little effect in rescuing severe bone marrow abnormalities.</p><p>Some individuals with low serum immunoglobulins and frequent infections may require treatment with intravenous immunoglobulin as well as antibiotics and antivirals in conjunction with anti-TNF agents [<a class="bk_pop" href="#ada2-def.REF.hashem.2017c.2682">Hashem et al 2017c</a>, <a class="bk_pop" href="#ada2-def.REF.schepp.2017.1689">Schepp et al 2017</a>].</p><p>Methotrexate is added when administering adalimumab or infliximab to prevent development of drug-related antibodies.</p><p><b>Thalidomide</b> is a potential treatment for TNF blockade when biologics are not available. Thalidomide is known to inhibit TNF production in dendritic cells and to exert an inhibitory effect on monocytes [<a class="bk_pop" href="#ada2-def.REF.deng.2003.1060">Deng et al 2003</a>]. Of note, in a study of six patients, all responded completely to thalidomide treatment; subsequently, however, the drug had to be discontinued (after treatment ranging from 20 months to 5 years) in three of the six due to neurologic toxicity [<a class="bk_pop" href="#ada2-def.REF.caorsi.2017.1648">Caorsi et al 2017</a>]. A study evaluating long-term thalidomide treatment in patients with multiple myeloma characterized neurologic toxicity as sensory peripheral neuropathy, including paraesthesias, tremor, and dizziness [<a class="bk_pop" href="#ada2-def.REF.tosi.2005.212">Tosi et al 2005</a>].</p><p><b>Steroids and general immunosuppressive therapies</b> (e.g., azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, and tacrolimus) have had variable success.</p><p><b>Anti-IL-6 therapy</b> was successfully used in a patient with DADA2 whose manifestations mimicked multicentric Castleman disease [<a class="bk_pop" href="#ada2-def.REF.van_nieuwenhove.2018.142">Van Nieuwenhove et al 2018</a>].</p><p><b>Hematopoietic stem cell transplantation (HSCT)</b> can be curative in individuals in whom bone marrow failure and/or immune dysregulation predominate, and who fail to respond to TNF inhibitor treatment. Successful HSCT returns plasma ADA2 activity to normal levels. In one study the hematologic and immunologic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> resolved post HSCT in all 14 patients with bone marrow dysfunction or immunodeficiency (6 of whom also had vasculitis); however, acute and moderate chronic autoimmunity and graft-versus-host disease were reported [<a class="bk_pop" href="#ada2-def.REF.hashem.2017c.2682">Hashem et al 2017c</a>].</p></div><div id="ada2-def.Current_Treatment_for_Asymptoma"><h4>Current Treatment for Asymptomatic Persons with Biallelic DADA2-Causing Variants in <i>ADA2</i></h4><p>Currently there are no predictors of which individual with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ADA2</i> pathogenic variants will develop a stroke or when a stroke may occur. Because of the potentially devastating consequences of stroke, the authors treat all individuals who have biallelic <i>ADA2</i> pathogenic variants with anti-TNF agents to reduce the risk of stroke.</p></div></div><div id="ada2-def.Surveillance"><h3>Surveillance</h3><p>Suggested follow-up evaluations include the following:</p><ul><li class="half_rhythm"><div>Complete physical examination (performed yearly or sooner if clinically indicated):</div><ul><li class="half_rhythm"><div>Blood pressure and other vital signs</div></li><li class="half_rhythm"><div>Skin examination</div></li><li class="half_rhythm"><div>Assessment for presence of lymphadenopathy and hepatosplenomegaly</div></li><li class="half_rhythm"><div>Neurologic examination for evidence of prior or recent strokes</div></li></ul></li><li class="half_rhythm"><div>Ophthalmologic examination for ptosis, abnormal eye movements, retinal infarcts, optic nerve damage</div></li><li class="half_rhythm"><div>ECG (if abnormal in the past). Note: Arterial hypertension, reported in 20% of patients, can lead to myocardial dysfunction.</div></li><li class="half_rhythm"><div>Laboratory assessment (performed yearly or sooner if clinically indicated):</div><ul><li class="half_rhythm"><div>CBC and differential</div></li><li class="half_rhythm"><div>ESR and CRP</div></li><li class="half_rhythm"><div>Kidney and liver function</div></li><li class="half_rhythm"><div>Quantitative serum immunoglobulins</div></li><li class="half_rhythm"><div>Lymphocyte phenotyping for evidence of a B-cell maturation defect</div></li><li class="half_rhythm"><div>Additionally, follow-up evaluation of abnormal laboratory studies identified at earlier evaluations</div></li></ul></li><li class="half_rhythm"><div>Imaging assessment (yearly or if clinically indicated):</div><ul><li class="half_rhythm"><div>Brain MRI if abnormal in the past or new symptoms or manifestations suggest brain involvement</div></li><li class="half_rhythm"><div>Peripheral MRA if symptoms of peripheral arterial disease and/or neurologic dysfunction</div></li><li class="half_rhythm"><div>Abdominal ultrasound examination to assess liver, spleen, and kidney size and hepatic blood flow</div></li><li class="half_rhythm"><div>FibroScan<sup>&#x000ae;</sup> ultrasound examination (if available) to assess hepatic elasticity for evidence of early portal hypertension</div></li></ul></li><li class="half_rhythm"><div>Liver biopsy (if clinically indicated) is the most reliable way to diagnose diffuse hepatic disease (e.g., in the presence of portal hypertension).</div></li></ul></div><div id="ada2-def.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Antiplatelet medications including aspirin</div></li><li class="half_rhythm"><div>Anticoagulation medications (except in the presence of atrial fibrillation)</div></li><li class="half_rhythm"><div>Smoking, which may exacerbate peripheral arterial disease</div></li></ul></div><div id="ada2-def.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>ADA2</i> pathogenic variants who are currently symptomatic and would benefit from prompt initiation of treatment and those who are currently asymptomatic and would benefit from treatment with anti-TNF agents to reduce the risk of stroke.</p><p>See <a href="#ada2-def.Related_Genetic_Counseling_Issu">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ada2-def.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Information regarding the safety of use of anti-TNF agents during pregnancy is limited. One study evaluating use of anti-TNF agents in pregnant women with inflammatory bowel disease determined that these drugs can cross the placenta from the latter part of the second trimester of gestation, though they are low risk in the short term [<a class="bk_pop" href="#ada2-def.REF.gisbert.2013.1426">Gisbert &#x00026; Chaparro 2013</a>].</p></div><div id="ada2-def.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="ada2-def.Genetic_Counseling"><h2 id="_ada2-def_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ada2-def.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Adenosine deaminase 2 deficiency (DADA2) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>ADA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not thought to be at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not thought to be at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Unless an individual with DADA2 has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> (see <a href="#ada2-def.Prevalence">Prevalence</a>), his/her offspring will be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ADA2</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>ADA2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="ada2-def.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>ADA2</i> pathogenic variants in the family.</p></div><div id="ada2-def.Related_Genetic_Counseling_Issu"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ada2-def.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ada2-def.Prenatal_Testing_and_Preimplant"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ADA2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="ada2-def.Resources"><h2 id="_ada2-def_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>DADA2 Foundation</b></div><div><b>Email:</b> info@dada2.org</div><div><a href="http://www.dada2.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.dada2.org</a></div></li><li class="half_rhythm"><div><b>Canadian Immunodeficiencies Patient Organization (CIPO)</b></div><div>362 Concession Road 12</div><div>RR #2</div><div>Hastings Ontario K0L 1Y0</div><div>Canada</div><div><b>Phone:</b> 877-262-2476 (toll-free)</div><div><b>Fax:</b> 866-942-7651 (toll-free)</div><div><b>Email:</b> info@cipo.ca</div><div><a href="http://cipo.ca" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cipo.ca</a></div></li><li class="half_rhythm"><div><b>Immune Deficiency Foundation</b></div><div>110 West Road</div><div>Suite 300</div><div>Towson MD 21204</div><div><b>Email:</b> idf@primaryimmune.org</div><div><a href="http://www.primaryimmune.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.primaryimmune.org</a></div></li><li class="half_rhythm"><div><b>International Patient Organisation for Primary Immunodeficiencies (IPOPI)</b></div><div>Firside</div><div>Main Road</div><div>Downderry Cornwall PL11 3LE</div><div>United Kingdom</div><div><b>Phone:</b> +44 01503 250 668</div><div><b>Fax:</b> +44 01503 250 668</div><div><b>Email:</b> info@ipopi.org</div><div><a href="http://ipopi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ipopi.org</a></div></li><li class="half_rhythm"><div><b>Jeffrey Modell Foundation/National Primary Immunodeficiency Resource Center</b></div><div>747 Third Avenue</div><div>New York NY 10017</div><div><b>Phone:</b> 866-463-6474 (toll-free); 212-819-0200</div><div><b>Fax:</b> 212-764-4180</div><div><b>Email:</b> info@jmfworld.org</div><div><a href="http://www.info4pi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.info4pi.org</a></div></li><li class="half_rhythm"><div><b>Vasculitis Foundation</b></div><div>PO Box 28660</div><div>Kansas City 64188</div><div><b>Phone:</b> 816-436-8211; 800-277-9474</div><div><b>Fax:</b> 816-656-3838</div><div><a href="https://www.vasculitisfoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.vasculitisfoundation.org</a></div></li><li class="half_rhythm"><div><b>DADA2 Foundation Registry</b></div><div><a href="http://www.dada2.org/registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.dada2.org/registry</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li><li class="half_rhythm"><div><b>RDCRN Patient Contact Registry: Primary Immune Deficiency Treatment Consortium</b></div><div><a href="https://www.rarediseasesnetwork.org/cms/pidtc" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Contact Registry</a></div></li></ul></div><div id="ada2-def.Molecular_Genetics"><h2 id="_ada2-def_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ada2-def.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Adenosine Deaminase 2 Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK544951/table/ada2-def.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ada2-def.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ada2-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ada2-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ada2-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ada2-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ada2-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ada2-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/51816" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ADA2</i></a></td><td headers="hd_b_ada2-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=51816" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q11<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_ada2-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9NZK5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Adenosine deaminase 2</a></td><td headers="hd_b_ada2-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ADA2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ADA2</a></td><td headers="hd_b_ada2-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ADA2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ADA2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ada2-def.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ada2-def.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Adenosine Deaminase 2 Deficiency (<a href="/omim/607575,615688" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK544951/table/ada2-def.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ada2-def.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607575" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607575</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ADENOSINE DEAMINASE 2; ADA2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/615688" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">615688</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME; VAIHS</td></tr></tbody></table></div></div><div id="ada2-def.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Humans express two enzymes, ADA1 (also referred to as ADA) (see <a href="/books/n/gene/ada/">Adenosine Deaminase Deficiency</a>) and ADA2, which catalyze the deamination of adenosine and 2'-deoxyadenosine to inosine and deoxyinosine, respectively. Although homologous proteins that are considered isozymes, ADA1 and ADA2 differ substantially in structure, including the arrangement of the substrate-binding pocket in the catalytic center [<a class="bk_pop" href="#ada2-def.REF.zavialov.2010b.12367">Zavialov et al 2010b</a>]. As a result, the affinity of ADA2 for adenosine is 100-fold lower than that of ADA1.</p><p>ADA1 is a largely intracellular protein, whereas ADA2 is a secreted protein. It has been postulated that ADA2 may control the level of extracellular adenosine (generated by stepwise dephosphorylation of extracellular ATP and AMP) and regulate a variety of biologic processes (through 4 distinct adenosine receptors expressed on many cells in the brain and immune and cardiovascular systems).</p><ul><li class="half_rhythm"><div><b>Activation.</b> Under stress conditions, hypoxia, ischemia, or inflammation, adenosine concentration increases due to excessive ATP breakdown.</div></li><li class="half_rhythm"><div><b>Signal termination.</b> Adenosine signaling is terminated by adenosine uptake from the extracellular space towards the intracellular space through nucleoside transporters, followed by metabolic conversion in the presence of adenosine kinase (to AMP) or deaminase (to inosine). Thus, the deamination step is critical for regulation of many signaling pathways including immune responses.</div></li></ul><p><b>Gene structure.</b>
<i>ADA2</i> spans about 43,000 base pairs and comprises ten exons. The codon for translation initiation (p.1Met) is located in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2.</p><p>See <a href="/books/NBK544951/#ada2-def.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Pathogenic variants</b> are loss of function. The majority of pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants; however, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants as well as small and large deletions have also been reported. Pathogenic missense variants are located in different regions of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and do not cluster to a specific <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a>.</p><div id="ada2-def.T.notable_ada2_pathogenic_varia" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Notable <i>ADA2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK544951/table/ada2-def.T.notable_ada2_pathogenic_varia/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ada2-def.T.notable_ada2_pathogenic_varia_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_1" rowspan="7" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001282225.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001282225<wbr style="display:inline-block"></wbr>​.1</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/532691754" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001269154<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.139G&#x0003e;A</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly47Arg</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder variant in Israeli, Georgian-Jewish, &#x00026; Turkish populations [<a class="bk_pop" href="#ada2-def.REF.hashem.2017b.70">Hashem et al 2017b</a>]</td></tr><tr><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.140G&#x0003e;C</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly47Ala</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Found in multiple populations</td></tr><tr><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.506G&#x0003e;A</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg169Gln</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder variant in individuals of Finnish or Dutch ancestry [<a class="bk_pop" href="#ada2-def.REF.van_montfrans.2016.902">Van Montfrans et al 2016</a>]</td></tr><tr><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.752C&#x0003e;T</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro251Leu</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low ADA2 activity with <a class="def" href="/books/n/gene/glossary/def-item/variable-expressivity/">variable expressivity</a> of clinical features [<a class="bk_pop" href="#ada2-def.REF.nanthapisal.2016.2314">Nanthapisal et al 2016</a>]</td></tr><tr><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1078A&#x0003e;G</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr360Ala</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Found more commonly in individuals of Italian ancestry [<a class="bk_pop" href="#ada2-def.REF.caorsi.2017.1648">Caorsi et al 2017</a>]</td></tr><tr><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1358A&#x0003e;G</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr453Cys</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Most common pan ethnic variant [<a class="bk_pop" href="#ada2-def.REF.hashem.2017b.70">Hashem et al 2017b</a>]</td></tr><tr><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c. 973-2 A&#x0003e;G</td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Aberrant <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a></td><td headers="hd_h_ada2-def.T.notable_ada2_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Found in multiple populations</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> ADA2 is a 59-kd monomer protein made up of 511 amino acids. It has four domains:</p><ul><li class="half_rhythm"><div>Dimerization</div></li><li class="half_rhythm"><div>Catalytic</div></li><li class="half_rhythm"><div>Putative receptor binding</div></li><li class="half_rhythm"><div>Substrate binding</div></li></ul><p>ADA2 forms a homodimer and localizes to the extracellular space where it may reduce the extracellular adenosine concentration.</p><p>ADA2 has four aspargine glycosylation sites at p.Asn127, p.Asn174, p.Asn185, and p.Asn378 [<a class="bk_pop" href="#ada2-def.REF.zavialov.2010a.279">Zavialov et al 2010a</a>]. Glycosylation plays an important role in ADA2 secretion by modulating ADA2 trafficking from the endoplasmic reticulum (ER) to the Golgi. Alteration of one consensus glycosylation sequence constituted by p.Thr129 and p.Asn127 has been shown to lead to ER retention and defective secretion of the abnormal ADA2 [<a class="bk_pop" href="#ada2-def.REF.lee.2018.1363">Lee et al 2018</a>].</p><p>ADA2 is predominately expressed in myeloid cells such as monocytes, macrophages, and dendritic cells. ADA2 is secreted by activated myeloid cells. Although it has been postulated that ADA2 decreases extracellular adenosine concentration at the sites of inflamed or tumor tissues, this has not been shown either in vitro or in vivo. Where measured, adenosine has not been elevated in the plasma of individuals with DADA2 [<a class="bk_pop" href="#ada2-def.REF.van_eyck.2015.283">Van Eyck et al 2015</a>], in contrast to the elevated levels found in individuals with ADA deficiency (see <a href="/books/n/gene/ada/">Adenosine Deaminase Deficiency</a>). Numerous studies report elevated levels of ADA2 in the serum of individuals with HIV and chronic inflammatory diseases, as well as in tuberculous pleural effusions.</p><p>ADA2 has homology to so-called adenosine deaminase growth factors (ADGFs) identified in several insect species, fish, and frogs. Although ADA2 is found in many species, mice lack an <i>ADA2</i> ortholog, which has hampered in vivo studies of ADA2 function. ADGFs may control tissue growth by modulating the level of extracellular adenosine [<a class="bk_pop" href="#ada2-def.REF.zurovec.2002.4403">Zurovec et al 2002</a>, <a class="bk_pop" href="#ada2-def.REF.zavialov.2010a.279">Zavialov et al 2010a</a>]. ADA2 also binds proteoglycans and adenosine receptors on immune cells, implying a role in cell signaling.</p><p>The role of ADA2 in multilineage hematopoiesis remains unclear. It is unknown if ADA2 plays additional roles in the development of bone marrow precursors or if the bone marrow failure in DADA2 may be related to inflammatory cell infiltration [<a class="bk_pop" href="#ada2-def.REF.meyts.2018.569">Meyts &#x00026; Aksentijevich 2018</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants are found in all protein domains and may affect protein secretion, dimerization or catalytic activity. Essentially, all pathogenic variants lead to decreased or complete loss of ADA2 protein expression and catalytic activity, one of the diagnostic features of DADA2. Lack of protein activity compromises several cellular processes that contribute to DADA2 pathogenesis (see <a href="#ada2-def.Molecular_Pathogenesis">Molecular Pathogenesis</a>).</p><p>In ADA2 deficiency an imbalance between anti-inflammatory M2 and proinflammatory M1 macrophages may create a hyper-inflammatory environment that is damaging to blood vessels [<a class="bk_pop" href="#ada2-def.REF.zhou.2014.911">Zhou et al 2014</a>]. Another study showed that adenosine can induce formation of neutrophil extracellular traps and also identified circulating low-density granulocytes, suggesting that neutrophils further contribute to the inflammatory <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#ada2-def.REF.carmonarivera.2019">Carmona-Rivera et al 2019</a>]. Activated myeloid cells can inflict damage to endothelial cells, causing vasculopathy/vasculitis. This effect of the ADA2-deficient myeloid cells on endothelial cells can be reversed with treatment with anti-TNF agents (see <a href="#ada2-def.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p></div></div><div id="ada2-def.References"><h2 id="_ada2-def_References_">References</h2><div id="ada2-def.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.alabbas.2019.26">Alabbas F, Elyamany G, Alsharif O, Hershfield M, Meyts I. Childhood Hodgkin lymphoma: Think DADA2. <span><span class="ref-journal">J Clin Immunol. </span>2019;<span class="ref-vol">39</span>:26–9.</span> [<a href="/pubmed/30644014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30644014</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.alsultan.2018.65">Alsultan A, Basher E, Alqanatish J, Mohammed R, Alfadhel M. Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2018:65.</span> [<a href="/pubmed/29271561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29271561</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.arts.2018.836">Arts K, Bergerson J, Ombrello AK, Similuk M, Oler AJ, Agharahimi A, Mace EM, Hershfield M, Wouters C, De Somer L, Morren MA, Diego RP, Moens L, Freeman AF, Meyts I. Warts and DADA2: a mere coincidence? <span><span class="ref-journal">J Clin Immunol. </span>2018;<span class="ref-vol">38</span>:836–43.</span> [<a href="/pubmed/30386947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30386947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.barzaghi.2019.2767">Barzaghi F, Minniti F, Mauro M, Bortoli M, Balter R, Bonetti E, Zaccaron A, Vitale V, Omrani M, Zoccolillo M, Brigida I, Cicalese MP, Degano M, Hershfield MS, Aiuti A, Bondarenko AV, Chinello M, Cesaro S. ALPS-like phenotype caused by ADA2 deficiency rescued by allogeneic hematopoietic stem cell transplantation. <span><span class="ref-journal">Front Immunol. </span>2019;<span class="ref-vol">9</span>:2767.</span> [<a href="/pmc/articles/PMC6339927/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6339927</span></a>] [<a href="/pubmed/30692987" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30692987</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.batu.2015.1532">Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, &#x000d6;zen S. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. <span><span class="ref-journal">J Rheumatol. </span>2015;<span class="ref-vol">42</span>:1532–4.</span> [<a href="/pubmed/26233953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26233953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.belot.2014.44">Belot A, Wassmer E, Twilt M, Lega JC, Zeef LA, Oojageer A, Kasher PR, Mathieu AL, Malcus C, Demaret J, Fabien N, Collardeau-Frachon S, Mechtouff L, Derex L, Walzer T, Rice GI, Durieu I, Crow YJ. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. <span><span class="ref-journal">Pediatr Rheumatol Online J. </span>2014;<span class="ref-vol">12</span>:44.</span> [<a href="/pmc/articles/PMC4181355/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4181355</span></a>] [<a href="/pubmed/25278816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25278816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.benami.2016.316">Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield MS, Kelly SJ, Ganson NJ, Kfir-Erenfeld S, Weintraub M, Elpeleg O, Berkun Y, Stepensky P. Extending the clinical phenotype of adenosine deaminase 2 deficiency. <span><span class="ref-journal">J Pediatr. </span>2016;<span class="ref-vol">177</span>:316–20.</span> [<a href="/pubmed/27514238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27514238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.bulut.2019.193">Bulut E, Erden A, Karadag O, Oguz KK, Ozen S. Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. <span><span class="ref-journal">J Neuroradiol. </span>2019;<span class="ref-vol">46</span>:193–8.</span> [<a href="/pubmed/29913178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29913178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.caorsi.2017.1648">Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, Conti G, Marchetti F, Picco P, Tommasini A, Martino S, Malattia C, Gallizi R, Podda RA, Salis A, Falcini F, Schena F, Garbarino F, Morreale A, Pardeo M, Ventrici C, Passarelli C, Zhou Q, Severino M, Gandolfo C, Damonte G, Martini A, Ravelli A, Aksentijevich I, Ceccherini I, Gattorno M. ADA2 deficiency (DADA2) as an unrecognized cause of early onset polyarteritis nodosa and stroke: a multicenter national study. <span><span class="ref-journal">Ann Rheum Dis. </span>2017;<span class="ref-vol">76</span>:1648–56.</span> [<a href="/pubmed/28522451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28522451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.caorsi.2016.51">Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. <span><span class="ref-journal">Pediatr Rheumatol Online J. </span>2016;<span class="ref-vol">14</span>:51.</span> [<a href="/pmc/articles/PMC5015262/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5015262</span></a>] [<a href="/pubmed/27609179" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27609179</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.carmonarivera.2019">Carmona-Rivera C, Khaznadar SS, Shwin KW, Irizarry-Caro JA, O'Neil LJ, Liu Y, Jacobson KA, Ombrello AK, Stone DL, Tsai WL, Kastner DL, Aksentijevich I, Kaplan MJ, Grayson PC. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. <span><span class="ref-journal">Blood. </span>2019.</span> Epub ahead of print. [<a href="/pmc/articles/PMC6659253/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6659253</span></a>] [<a href="/pubmed/31015188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31015188</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.cipe.2018.273">Cipe FE, Aydogmus C, Serwas NK, Keskindemirci G, Boztug K. Novel mutation in CECR1 leads to deficiency of ADA2 with associated neutropenia. <span><span class="ref-journal">J Clin Immunol. </span>2018;<span class="ref-vol">38</span>:273–7.</span> [<a href="/pubmed/29564582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29564582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.deng.2003.1060">Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. <span><span class="ref-journal">J Invest Dermatol. </span>2003;<span class="ref-vol">121</span>:1060–5.</span> [<a href="/pubmed/14708607" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14708607</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.fellmann.2016.1189">Fellmann F, Angelini F, Wassenberg J, Perreau M, Arenas Ramirez N, Simon G, Boyman O, Demaria O, Christen-Zaech S, Hohl D, Belfiore M, von Scheven-Gete A, Gilliet M, Bochud PY, Perrin Y, Beck Popovic M, Bart PA, Beckmann JS, Martinet D, Hofer M. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2016;<span class="ref-vol">137</span>:1189–96.e2.</span> [<a href="/pubmed/26607704" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26607704</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.garg.2014.827">Garg N, Kasapcopur O, Foster J 2nd, Barut K, Tekin A, K&#x00131;z&#x00131;lk&#x00131;l&#x00131;&#x000e7; O, Tekin M. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. <span><span class="ref-journal">Eur J Pediatr. </span>2014;<span class="ref-vol">173</span>:827–30.</span> [<a href="/pubmed/24737293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24737293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.ghurye.2019.e60">Ghurye RR, Sundaram K, Smith F, Clark B, Simpson MA, Fairbanks L, Adhya Z, Mufti GJ, Marsh JCW, Ibrahim MAA. Novel ADA2 mutation presenting with neutropenia, lymphopenia and bone marrow failure in patients with deficiency in adenosine deaminase 2 (DADA2). <span><span class="ref-journal">Br J Haematol. </span>2019;<span class="ref-vol">186</span>:e60–e64.</span> [<a href="/pubmed/30924144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30924144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.gibson.2019">Gibson KM, Morishita KA, Dancey P, Moorehead P, Dr&#x000f6;gem&#x000f6;ller B, Han X, Graham J, Hancock RE, Foell D, Benseler S, Luqmani R, Yeung RSM, Shenoi S, Bohm M, Rosenberg AM, Ross CJ, Cabral DA, Brown KL, et al.  Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis. <span><span class="ref-journal">Arthritis Rheumatol. </span>2019.</span> Epub ahead of print. [<a href="/pubmed/31008556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31008556</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.gisbert.2013.1426">Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. <span><span class="ref-journal">Am J Gastroenterol. </span>2013;<span class="ref-vol">108</span>:1426–38.</span> [<a href="/pubmed/23752881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23752881</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.goel.1999.318">Goel N, Ortel TL, Bali D, Anderson JP, Gourley IS, Smith H, Morris CA, DeSimone M, Branch DW, Ford P, Berdeaux D, Roubey RA, Kostyu DD, Kingsmore SF, Thiel T, Amos C, Seldin MF. Familial antiphospholipid antibody syndrome: criteria for disease and evidence for autosomal dominant inheritance. <span><span class="ref-journal">Arthritis Rheum. </span>1999;<span class="ref-vol">42</span>:318–27.</span> [<a href="/pubmed/10025927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10025927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.gonzalez_santiago.2015.1230">Gonzalez Santiago TM, Zavialov A, Saarela J, Seppanen M, Reed AM, Abraham RS, Gibson LE. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. <span><span class="ref-journal">JAMA Dermatol. </span>2015;<span class="ref-vol">151</span>:1230–34.</span> [<a href="/pubmed/26131734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26131734</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.grossi.2019.732">Grossi A, Cusano R, Rusmini M, Penco F, Schena F, Podda R. A, Caorsi R, Gattorno M, Uva P, Ceccherini I. ADA2 deficiency due to a novel structural variation in 22q11.1. <span><span class="ref-journal">Clin Genet. </span>2019;<span class="ref-vol">95</span>:732–3.</span> [<a href="/pubmed/30920658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30920658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.hademenos.2001.997">Hademenos GJ, Alberts MJ, Awad I, Mayberg M, Shepard T, Jagoda A, Latchaw RE, Todd HW, Viste K, Starke R, Girgus MS, Marler J, Emr M, Hart N. Advances in the genetics of cerebrovascular disease and stroke. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:997–1008.</span> [<a href="/pubmed/11339244" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11339244</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.hashem.2017a.e293">Hashem H, Egler R, Dalal J. Refractory pure red cell aplasia manifesting as deficiency of adenosine deaminase 2. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2017a;<span class="ref-vol">39</span>:e293–e296.</span> [<a href="/pubmed/28230570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28230570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.hashem.2017b.70">Hashem H, Kelly SJ, Ganson NJ, Hershfield MS. Deficiency of adenosine deaminase 2 (DADA2), an inherited cause of polyarteritis nodosa and a mimic of other systemic rheumatologic disorders. <span><span class="ref-journal">Curr Rheumatol Rep. </span>2017b;<span class="ref-vol">19</span>:70.</span> [<a href="/pubmed/28983775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28983775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.hashem.2017c.2682">Hashem H, Kumar AR, M&#x000fc;ller I, Babor F, Bredius R, Dalal J, Hsu AP, Holland SM, Hickstein DD, Jolles S, Krance R, Sasa G, Taskinen M, Koskenvuo M, Saarela J, van Montfrans J, Wilson K, Bosch B, Moens L, Hershfield M, Meyts I, et al.  Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. <span><span class="ref-journal">Blood. </span>2017c;<span class="ref-vol">130</span>:2682–8.</span> [<a href="/pmc/articles/PMC5731089/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5731089</span></a>] [<a href="/pubmed/28974505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28974505</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.hsu.2016">Hsu AP, West RR, Calvo KR, Cuellar-Rodriguez J, Parta M, Kelly SJ, Ganson NJ, Hershfield MS, Holland SM, Hickstein DD. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2016;138:628-30 e2. [<a href="/pmc/articles/PMC4975951/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4975951</span></a>] [<a href="/pubmed/27130863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27130863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.lee.2018.282">Lee PY. Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2. <span><span class="ref-journal">Front Pediatr. </span>2018;<span class="ref-vol">6</span>:282.</span> [<a href="/pmc/articles/PMC6200955/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6200955</span></a>] [<a href="/pubmed/30406060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30406060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.lee.2018.1363">Lee PY, Huang Y, Zhou Q, Schnappauf O, Hershfield MS, Li Y, Ganson NJ, Sampaio Moura N, Delmonte OM, Stone SS, Rivkin MJ, Pai SY, Lyons T, Sundel RP, Hsu VW, Notarangelo LD, Aksentijevich I, Nigrovic PA. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2018;<span class="ref-vol">142</span>:1363–5.e8.</span> [<a href="/pmc/articles/PMC6175612/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6175612</span></a>] [<a href="/pubmed/29936104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29936104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.meyts.2018.569">Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. <span><span class="ref-journal">J Clin Immunol. </span>2018;<span class="ref-vol">38</span>:569–78.</span> [<a href="/pmc/articles/PMC6061100/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6061100</span></a>] [<a href="/pubmed/29951947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29951947</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.michniacki.2018.166">Michniacki TF, Hannibal M, Ross CW, Frame DG, DuVall AS, Khoriaty R, Vander Lugt MT, Walkovich KJ. Hematologic manifestations of deficiency of adenosine deaminase 2 (DADA2) and response to tumor necrosis factor inhibition in DADA2-associated bone marrow failure. <span><span class="ref-journal">J CLin Immunol. </span>2018;<span class="ref-vol">38</span>:166–73.</span> [<a href="/pubmed/29411230" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29411230</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.nanthapisal.2016.2314">Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour K, Klein NJ, Eleftheriou D, Brogan PA. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. <span><span class="ref-journal">Arthritis Rheumatol. </span>2016;<span class="ref-vol">68</span>:2314–22.</span> [<a href="/pubmed/27059682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27059682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.navon_elkan.2014.921">Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, Voth I, Hashkes PJ, Harel L, Hoffer V, Ling E, Yalcinkaya F, Kasapcopur O, Lee MK, Klevit RE, Renbaum P, Weinberg-Shukron A, Sener EF, Schormair B, Zeligson S, Marek-Yagel D, Strom TM, Shohat M, Singer A, Rubinow A, Pras E, Winkelmann J, Tekin M, Anikster Y, King MC, Levy-Lahad E. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">370</span>:921–31.</span> [<a href="/pubmed/24552285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.ombrello.2019.1582">Ombrello AK, Qin J, Hoffmann PM, Kumar P, Stone D, Jones A, Romeo T, Barham B, Pinto-Patarroyo G, Toro C, Soldatos A, Zhou Q, Deuitch N, Aksentijevich I, Sheldon SL, Kelly S, Man A, Barron K, Hershfield M, Flegel WA, Kastner DL. Treatment strategies for deficiency of adenosine deaminase 2. <span><span class="ref-journal">N Engl J Med. </span>2019;<span class="ref-vol">380</span>:1582–4.</span> [<a href="/pubmed/30995379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30995379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.rama.2018.960">Rama M, Duflos C, Melki I, Bessis D, Bonhomme A, Martin H, Doummar D, Valence S, Rodriguez D, Carme E, Genevieve D, Heimdal K, Insalaco A, Franck N, Queyrel-Moranne V, Tieulie N. London J, Uettwiller F, Georgin-Lavialle S, Belot A, Kon&#x000e9;-Paut I, Hentgen V, Boursier G, Touitou I, Sarrabay G. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. <span><span class="ref-journal">Eur J Hum Genet. </span>2018;<span class="ref-vol">26</span>:960–71.</span> [<a href="/pmc/articles/PMC6018671/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6018671</span></a>] [<a href="/pubmed/29681619" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29681619</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.sahin.2019">Sahin S, Adrovic A, Barut K, Baran S, Tahir Turanli E, Canpolat N, Kizilkilic O, Ozkaya O, Kasapcopur O. A. 9.5-year-old boy with recurrent neurological manifestations and severe hypertension, treated initially for polyarteritis nodosa, was subsequently diagnosed with adenosine deaminase type 2 deficiency (DADA2) which responded to anti-TNF-&#x003b1;. <span><span class="ref-journal">Paediatr Int Child Health. </span>2019.</span> Epub ahead of print. [<a href="/pubmed/30642227" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30642227</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.sahin.2018.129">Sahin S, Adrovic A, Barut K, Ugurlu S, Turanli ET, Ozdogan H, Kasapcopur O. Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. <span><span class="ref-journal">Rheumatol Int. </span>2018;<span class="ref-vol">38</span>:129–36.</span> [<a href="/pubmed/28516235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28516235</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.schepp.2016.179">Schepp J, Bulashevska A, Mannhardt-Laakmann W, Cao H, Yang F, Seidl M, Kelly S, Hershfield M, Grimbacher B. Deficiency of adenosine deaminase 2 causes antibody deficiency. <span><span class="ref-journal">J Clin Immunol. </span>2016;<span class="ref-vol">36</span>:179–86.</span> [<a href="/pubmed/26922074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26922074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.schepp.2017.1689">Schepp J, Proietti M, Frede N, Buchta M, H&#x000fc;bscher K, Rojas Restrepo J, Goldacker S, Warnatz K, Pachlopnik Schmid J, Duppenthaler A, Lougaris V, Uriarte I, Kelly S, Hershfield M, Grimbacher B. Screening of 181 patients with antibody deficiency for ada2 sheds new light on the disease in adulthood. <span><span class="ref-journal">Arthritis Rheumatol. </span>2017;<span class="ref-vol">69</span>:1689–700.</span> [<a href="/pubmed/28493328" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28493328</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.skrablbaumgartner.2017.67">Skrabl-Baumgartner A, Plecko B, Schmidt WM, K&#x000f6;nig N, Hershfield M, Gruber-Sedlmayr U, Lee-Kirsch MA. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. <span><span class="ref-journal">Pediatr Rheumatol Online J. </span>2017;<span class="ref-vol">15</span>:67.</span> [<a href="/pmc/articles/PMC5568374/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5568374</span></a>] [<a href="/pubmed/28830446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28830446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.s_nmez.2018.1563">S&#x000f6;nmez HE, Batu ED, Ta&#x0015f;k&#x00131;ran EZ, Alika&#x0015f;ifo&#x0011f;lu M, Bilginer Y, &#x000d6;zen S. Genetic testing for DADA2: How can we avoid missing patients? <span><span class="ref-journal">Eur J Hum Genet. </span>2018;<span class="ref-vol">26</span>:1563–5.</span> [<a href="/pmc/articles/PMC6189089/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6189089</span></a>] [<a href="/pubmed/30206352" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30206352</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.springer.2018.1361">Springer JM, Gierer SA, Jiang H, Kleiner D, Deuitch N, Ombrello AK, Grayson PC, Aksentijevich I. Deficiency of adenosine deaminase 2 in adult siblings: many years of a misdiagnosed disease with severe consequences. <span><span class="ref-journal">Front Immunol. </span>2018;<span class="ref-vol">9</span>:1361.</span> [<a href="/pmc/articles/PMC6010516/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6010516</span></a>] [<a href="/pubmed/29963054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29963054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.szmyrkakaczmarek.2005">Szmyrka-Kaczmarek M, Daikeler, T, Benz D, Koetter I. Familial inflammatory Sneddon&#x02019;s syndrome-case report and review of the literature. Clin rheum. 2005;24:79-82. [<a href="/pubmed/15340865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15340865</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.tosi.2005.212">Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M. Neurological toxicity of long-term (&#x0003e;1 yr) thalidomide therapy in patients with multiple myeloma. <span><span class="ref-journal">Eur J Haematol. </span>2005;<span class="ref-vol">74</span>:212–6.</span> [<a href="/pubmed/15693790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15693790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.trotta.2018.1534">Trotta L, Martelius T, Siitonen T, Hautala T, H&#x000e4;m&#x000e4;l&#x000e4;inen S, Juntti H, Taskinen M, Ilander M, Andersson EI, Zavialov A, Kaustio M, Keski-Filppula R, Hershfield M, Mustjoki S, Tapiainen T, Sepp&#x000e4;nen M, Saarela J. ADA2 deficiency: clonal lymphoproliferation in a subset of patients. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2018;<span class="ref-vol">141</span>:1534–7.e8.</span> [<a href="/pubmed/29391253" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29391253</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.uettwiller.2016.e000236">Uettwiller F, Sarrabay G, Rodero MP, Rice GI, Lagrue E, Marot Y, Deiva K, Touitou I, Crow YJ, Quartier P. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. <span><span class="ref-journal">RMD Open. </span>2016;<span class="ref-vol">2</span>:e000236.</span> [<a href="/pmc/articles/PMC4879337/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4879337</span></a>] [<a href="/pubmed/27252897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27252897</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.van_eyck.2015.283">Van Eyck L Jr, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, Frans G, Schaballie H, De Hertogh G, Dooley J, Bossuyt X, Wouters C, Liston A, Meyts I. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2015;<span class="ref-vol">135</span>:283–7.e5.</span> [<a href="/pmc/articles/PMC4282724/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4282724</span></a>] [<a href="/pubmed/25457153" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25457153</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.van_montfrans.2016.902">Van Montfrans JM, Hartman EAR, Braun KPJ, Hennekam EAM, Elisabeth A, Hak EA, Nederkoorn PJ, Westendorp WF. Bredius RGM, Kollen WJW, Sch&#x000f6;lvinck EH, Legger GE, Meyts I, Liston A, Lichtenbelt KD, Giltay JC, Van Haaften G, De Vries Simons GM, Leavis H, Sanders CJG, Bierings MB, Stefan Nierkens S, Van Gijn ME. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. <span><span class="ref-journal">Rheumatology. </span>2016;<span class="ref-vol">55</span>:902–10.</span> [<a href="/pubmed/26867732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26867732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.van_nieuwenhove.2018.142">Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, De Somer L, Dooley J, Tousseyn T, Hershfield M, Liston A, Wouters C. ADA2 deficiency mimicking idiopathic multicentric Castleman disease. <span><span class="ref-journal">Pediatrics. </span>2018:142.</span> [<a href="/pubmed/30139808" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30139808</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.zavialov.2010a.279">Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. <span><span class="ref-journal">J Leukoc Biol. </span>2010a;<span class="ref-vol">88</span>:279–90.</span> [<a href="/pubmed/20453107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20453107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.zavialov.2010b.12367">Zavialov AV, Yu X, Spillmann D, Lauvau G, Zavialov AV. Structural basis for the growth factor activity of human adenosine deaminase ADA2. <span><span class="ref-journal">J Biol Chem. </span>2010b;<span class="ref-vol">285</span>:12367–77.</span> [<a href="/pmc/articles/PMC2852975/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2852975</span></a>] [<a href="/pubmed/20147294" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20147294</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.zhou.2014.911">Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I. Early-onset stroke and vasculopathy associated with mutations in ADA2. <span><span class="ref-journal">N Engl J Med. </span>2014;<span class="ref-vol">370</span>:911–20.</span> [<a href="/pmc/articles/PMC4193683/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4193683</span></a>] [<a href="/pubmed/24552284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ada2-def.REF.zurovec.2002.4403">Zurovec M, Dolezal T, Gazi M, Pavlova E, Bryant PJ. Adenosine deaminase-related growth factors stimulate cell proliferation in Drosophila by depleting extracellular adenosine. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2002;<span class="ref-vol">99</span>:4403–08.</span> [<a href="/pmc/articles/PMC123660/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC123660</span></a>] [<a href="/pubmed/11904370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11904370</span></a>]</div></li></ul></div></div><div id="ada2-def.Chapter_Notes"><h2 id="_ada2-def_Chapter_Notes_">Chapter Notes</h2><div id="ada2-def.Author_Notes"><h3>Author Notes</h3><p>Natalia Sampaio Moura was a post-baccalaureate research fellow at the National Human Genome Research Institute, National Institutes of Health. Her work involves conducting genetic research studies and diagnostic sequencing of patients with autoinflammatory disorders including many patients with DADA2. She earned a Bachelor of Science degree with High Honors in the Cell Biology and Molecular Genetics department at the University of Maryland, College Park. Natalia is looking forward to starting medical school this year.</p><p>Dr Karyl Barron, a pediatric rheumatologist and immunologist, is the Deputy Director of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. She sees patients with autoinflammatory diseases at the National Institutes of Health where she has a large cohort of patients.</p><p>Dr Ivona Aksentijevich is an Associate Investigator in the National Human Genome Research Institute (NHGRI), National Institutes of Health. The laboratory focuses on identifying genes responsible for mediating inherited human disorders of inflammation. In addition to DADA2, autoinflammatory disorders identified by the laboratory include <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> mediterranean fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), neonatal-onset multisystem inflammatory disease (NOMID), autoinflammation PLC&#x003b3;2-associated antibody deficiency (APLAID), deficiency of IL-1RN (DIRA), <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> of A20 (HA20), and Otulin deficiency (otulipenia). The laboratory works to elucidate the mechanism of these genetic disorders in order to develop insights into possible targeted treatments. Dr Aksentijevich also runs a CLIA-certified diagnostic sequencing laboratory within the NHGRI.</p></div><div id="ada2-def.Acknowledgments"><h3>Acknowledgments</h3><p>We would like to acknowledge the <i>GeneReviews</i> Editors and Reviewers for their helpful advice and contributions to the development of this <i>GeneReview</i> chapter on ADA2.</p></div><div id="ada2-def.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>8 August 2019 (bp) Review posted live</div></li><li class="half_rhythm"><div>18 April 2019 (ia) Original submission</div></li></ul><p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <i>GeneReview</i> "Adenosine Deaminase 2 Deficiency" is in the public <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> in the United States of America.</p></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK544951</span><span class="label">PMID: <a href="/pubmed/31393689" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31393689</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/aprt-def/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ada/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK544951&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK544951/?report=reader">PubReader</a></li><li><a href="/books/NBK544951/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK544951" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK544951" style="display:none" title="Cite this Page"><div class="bk_tt">Aksentijevich I, Sampaio Moura N, Barron K. Adenosine Deaminase 2 Deficiency. 2019 Aug 8. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK544951/pdf/Bookshelf_NBK544951.pdf">PDF version of this page</a> (504K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ada2-def.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ada2-def.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ada2-def.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ada2-def.Genetically_Related_Allelic_Dis" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ada2-def.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ada2-def.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ada2-def.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ada2-def.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ada2-def.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ada2-def.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ada2-def.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=51816[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ADA2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4814912" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4814912" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4814912" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4814912" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29951947" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.</a><span class="source">[J Clin Immunol. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Meyts I, Aksentijevich I. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Immunol. 2018 Jul; 38(5):569-578. Epub 2018 Jun 27.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301656" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hershfield M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301446" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pastores GM, Hughes DA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27609179" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Monogenic polyarteritis: the lesson of ADA2 deficiency.</a><span class="source">[Pediatr Rheumatol Online J. 2016]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Monogenic polyarteritis: the lesson of ADA2 deficiency.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Caorsi R, Penco F, Schena F, Gattorno M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatr Rheumatol Online J. 2016 Sep 8; 14(1):51. Epub 2016 Sep 8.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30406060" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2.</a><span class="source">[Front Pediatr. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lee PY. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Front Pediatr. 2018; 6:282. Epub 2018 Oct 18.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31393689" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31393689" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040ffd75f66d18aac7b45d">Adenosine Deaminase 2 Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Adenosine Deaminase 2 Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:42:21-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CAEA1E03FDE21000000000735028B&amp;ncbi_session=CE8CAEA1E040FFC1_1845SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK544951%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK544951&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK544951/&amp;ncbi_pagename=Adenosine Deaminase 2 Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CAEA1E040FFC1_1845SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>